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Revista de la Sociedad Española de Nefrología
etters to the Editor
omment  on  “Cellular  and  molecular  aspects  of diabetic







6ephropathy;  the  role  of  VEGF-A”
ear Editor,
e  read the published article with the title of ‘Cellular
nd molecular aspects of diabetic nephropathy; the role of
EGF-A’1 with a great interest and we  found worth sharing
ur clinical observations through a case to contribute to the
heir determination.
Katherine Carranza et al.1 have stated that the experi-
ental conditions VEGF-A decreased or after treatment with
olecules developed against VEGF, it can be observed various
athologic processes such as glomerular basement membrane
amage, proteinuria, acute renal failure and thromboem-
olic events. Monoclonal antibodies that bind the VEGF has
ong been used in systemic treatment protocol of solid
umors. Recently, by ophthalmologists, intravitreal adminis-
ration of anti-VEGF agents seen as the primary treatment
ethod in conditions of age- related macular degenera-
ion, diabetic retinopathy, retinal vein occlusion.2 Although
ystemic side effects are well known with the high dose
ntravenous use in cancer therapy, almost local side effects
ere reported associated with intraocular anti-VEGF treat-
ent. However, despite the blood retinal barrier, anti-VEGF
gents are detectable in systemic circulation after intraocular
dministration through uveal vessels or by aqueous humor
utﬂow and might constitutes systemic adverse effect like
ephropathy by antagonizing to VEGF-dependent pathway in
lomeruli.3
We  describe a case of nephrotic syndrome that were unable
o detect signiﬁcant ﬁndings for etiology in ﬁrst research. But
ith detailed history we  found that she had received intravi-
real anti-VEGF due to diabetic retinopathy 10 days before the
ccurrence of symptoms. After the exclusion of other possible
auses. We  thought anti-VEGF agents might be responsible.
n the literature, we  found only 3 cases associated with renal
oxicity of intraocular anti-VEGF therapy.4–6
We  would like to remind that even at the small quan-
ities used in the practice of ophthalmology, anti-VEGF
211-6995agents may able to cause serious systemic effects including
nephropathy.
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